- IN₹373.62bn
- IN₹567.42bn
- IN₹147.56bn
- 54
- 20
- 33
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 42.15 | ||
| PEG Ratio (f) | 0.43 | ||
| EPS Growth (f) | 3,130.57% | ||
| Dividend Yield (f) | 0.26% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.78 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 17.75 | ||
| Price to Sales | 2.53 | ||
| EV to EBITDA | 18.66 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.35% | ||
| Return on Equity | 4.02% | ||
| Operating Margin | 9.37% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 63,005 | 71,431 | 81,840 | 111,742 | 147,557 | 149,284.74 | 176,497.72 | 21.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -20.42 | -16.87 | +17.08 | -27.17 | +81.44 | -97.1 | +3130.57 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Diabetes, Oncology and Immunology. Its APIs pipeline includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Directors
- Kiran Mazumdar-Shaw CHM (68)
- Siddharth Mittal CEO (42)
- John Shaw NVC (72)
- Shreehas Tambe CEX
- Amitava Saha CHO
- Mayank Verma CCO
- Sriram A.V. OTH
- Seema Ahuja OTH
- Gopala Dasika OTH
- Prasad Deshpand OTH
- Vivek Gupta OTH
- Manoj Pananchukunnath OTH
- Paul Thomas OTH
- Nehal Vora OTH
- Abhijit Zutshi OTH
- Eric Mazumdar NED
- Ravi Mazumdar NED (66)
- Daniel Bradbury NID (60)
- Meleveetil Damodaran NID (74)
- Mary Harney NID (68)
- Vijay Kuchroo NID (66)
- Bobby Parikh NID (57)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 29th, 1978
- Public Since
- April 17th, 2004
- No. of Shareholders
- 470,261
- No. of Employees
- 3,681
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 1,198,063,078
- Address
- 20th KM, Hosur Road, Electronic City,, BANGALORE, 560100
- Web
- https://www.biocon.com/
- Phone
- +91 8028082808
- Contact
- Saurabh Paliwal
- Auditors
- BSR & Co. LLP
Upcoming Events for BIOCON
Full Year 2025 Biocon Ltd Earnings Call
Q1 2026 Biocon Ltd Earnings Release
Biocon Ltd Annual Shareholders Meeting
Similar to BIOCON
Indo US Bio-Tech
National Stock Exchange of India
Onesource Specialty Pharma
National Stock Exchange of India
Suven Life Sciences
National Stock Exchange of India
Syngene International
National Stock Exchange of India
Take Solutions
National Stock Exchange of India
FAQ
What is the Biocon share price?
As of Today at 19:35 UTC, shares in Biocon are trading at IN₹311.85. This share price information is delayed by 15 minutes.
How has the Biocon share price performed this year?
Shares in Biocon last closed at IN₹311.85 and the price had moved by +6.93% over the past 365 days. In terms of relative price strength the Biocon share price has outperformed the S&P BSE 100 Index by +0.73% over the past year.
What are the analyst and broker recommendations for Biocon?
The overall consensus recommendation for Biocon is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Biocon dividend yield?
The Biocon dividend yield is 0.16% based on the trailing twelve month period.
Does Biocon pay a dividend?
Last year, Biocon paid a total dividend of IN₹0.50, and it currently has a trailing dividend yield of 0.16%. We do not have any data on when Biocon is to next pay dividends.
When does Biocon next pay dividends?
We do not have data on when Biocon is to next pay dividends. The historic dividend yield on Biocon shares is currently 0.16%.
How do I buy Biocon shares?
To buy shares in Biocon you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biocon?
As of the previous close price of IN₹311.85, shares in Biocon had a market capitalisation of IN₹373.62bn.
Where are Biocon shares listed?
Here are the trading details for Biocon:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BIOCON
What kind of share is Biocon?
Based on an overall assessment of its quality, value and momentum Biocon is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biocon share price forecast for 2025?
The analyst consensus target price for shares in Biocon is IN₹386.47. That is 23.93% above the last closing price of IN₹311.85.
Analysts covering Biocon currently have a consensus Earnings Per Share (EPS) forecast of IN₹0.23 for the next financial year.
Find out moreWhat is the trend in the Biocon share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocon. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +2.07%.
As of the last closing price of IN₹311.85, shares in Biocon were trading -11.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biocon PE Ratio?
The Biocon PE ratio based on its reported earnings over the past 12 months is 42.15. The shares last closed at IN₹311.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biocon?
Biocon's management team is headed by:
- Kiran Mazumdar-Shaw - CHM
- Siddharth Mittal - CEO
- John Shaw - NVC
- Shreehas Tambe - CEX
- Amitava Saha - CHO
- Mayank Verma - CCO
- Sriram A.V. - OTH
- Seema Ahuja - OTH
- Gopala Dasika - OTH
- Prasad Deshpand - OTH
- Vivek Gupta - OTH
- Manoj Pananchukunnath - OTH
- Paul Thomas - OTH
- Nehal Vora - OTH
- Abhijit Zutshi - OTH
- Eric Mazumdar - NED
- Ravi Mazumdar - NED
- Daniel Bradbury - NID
- Meleveetil Damodaran - NID
- Mary Harney - NID
- Vijay Kuchroo - NID
- Bobby Parikh - NID